Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory, Fibrotic, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCL7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCL7 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed for native conformation. |
View CCL7 Products |
| Gene Delivery | CCL7 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and chemotaxis assay validation. |
View CCL7 Products |
| Benchmark Ab | Anti-CCL7 Recombinant Antibody Recombinant positive control derived from clinical-grade benchmark sequences. |
View CCL7 Products |
| Validator | CCL7 siRNA Set Target-specific knockdown verification in functional primary cell assays. |
View CCL7 Products |
| Related Target A | CCR2 Primary G-protein coupled receptor for CCL7; critical for monocyte chemotaxis and infiltration assays. |
View CCR2 Products |
| Related Target B | CCL2 Highly homologous chemokine sharing the CCR2 receptor; critical for specificity and cross-reactivity counter-screening. |
View CCL2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High Sequence Homology Cross-Reactivity (CCL2 vs. CCL7) | Sequence-verified recombinant proteins with rigorous mass spectrometry characterization to ensure target-specific epitope presentation. |
| Endotoxin-Induced Artifacts in Primary Cell Assays | Strictly endotoxin-controlled formulations (<1.0 EU/μg) protecting sensitive monocyte/macrophage migration assays. |
| Lack of Validated Positive Controls | Sequence-defined recombinant benchmark antibodies available as positive controls for ligand-receptor blocking assays. |
| Inconsistent Transfection in Target Cells | High-titer premade lentiviral particles encoding full-length human CCL7 for robust, stable expression. |
Live CCL7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the CCL7 axis is rapidly gaining traction, driven by its pivotal role in regulating the immunosuppressive tumor microenvironment (TME) and driving fibrotic progression. While historical focus centered primarily on its sister chemokine CCL2, selective inhibition of CCL7 has emerged as a key strategy to avoid the compensatory signaling loops associated with broad CCR2 blockade. Current clinical and preclinical efforts are shifting from systemic chemokine sequestration toward localized delivery, bispecific targeting, and combination regimens with immune checkpoint inhibitors.
As next-generation therapies enter preclinical validation, the demand for highly characterized, native-conformation reagents is paramount. Developing therapies must demonstrate precise selectivity, distinguishing CCL7 from highly homologous family members (such as CCL2 and CCL8) to minimize off-target liabilities while maintaining high neutralizing potency.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Biotech & Academic Consortia | Inflammatory Bowel Disease (IBD), Rheumatoid Arthritis | High-purity, low-endotoxin CCL7 proteins for SPR-based affinity and kinetics validation. |
| Small Molecule Antagonists | Global Pharmaceutical Entities | NASH / MASH, Pulmonary Fibrosis | Stable CCR2/CCR1 cell lines generated via Lentiviral transduction for calcium flux and chemotaxis assays. |
| Bispecific Antibodies | Oncology-focused Biopharma | Solid Tumors (Pancreatic, Colorectal) | Dual-target binding assays requiring sequence-verified CCL7 and related pathway proteins (e.g., CCL2). |